- Conditions
- Cutaneous Squamous Cell Carcinoma
- Interventions
- Cemiplimab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 40
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma, Cervical Cancer
- Interventions
- RPTR-168
- Biological
- Lead sponsor
- Repertoire Immune Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Ann Arbor, Michigan + 1 more
- Conditions
- Recurrent or Metastatic Solid Tumors
- Interventions
- Ifinatamab deruxtecan
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Whittier, California • Skokie, Illinois + 12 more
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
- Interventions
- PDR001, ACZ885, CJM112, TMT212, EGF816
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more
- Conditions
- Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Interventions
- Raman Spectroscopy handheld probe (EmVision, FL, USA), Raman Spectroscopy laser source (Hubner Photonics Inc, CA, USA)
- Device
- Lead sponsor
- Tiezhi Zhang
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Interventions
- FT836, Paclitaxel, Cetuximab, Trastuzumab
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 5
- States / cities
- La Jolla, California • Minneapolis, Minnesota • Philadelphia, Pennsylvania + 1 more
- Conditions
- Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
- Interventions
- AZD8701, Durvalumab
- Drug · Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more
- Conditions
- Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Skin Cancer
- Interventions
- LN-145, Cyclophosphamide, Fludarabine, Interleukin-2
- Biological · Drug
- Lead sponsor
- Karam Khaddour, MD, MS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer
- Interventions
- ERAS-007, ERAS-601, Osimertinib, Sotorasib
- Drug
- Lead sponsor
- Erasca, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 11
- States / cities
- Duarte, California • Orange, California • Santa Monica, California + 7 more
- Conditions
- Basal Cell Carcinoma of Skin, Squamous Cell Carcinoma (Skin)
- Interventions
- Two photon microscopy imaging
- Device
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- Not listed
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Victor, New York
- Conditions
- Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
- Interventions
- BCA101, Pembrolizumab
- Drug
- Lead sponsor
- Bicara Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 15
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 10 more
- Conditions
- Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
- Interventions
- cetuximab, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Ovarian Cancer, NSCLC, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer (TNBC)
- Interventions
- NRM-823
- Drug
- Lead sponsor
- Normunity AccelCo, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Denver, Colorado • New Haven, Connecticut • Minneapolis, Minnesota + 6 more
- Conditions
- Advanced Solid Tumor
- Interventions
- CDK-002
- Biological
- Lead sponsor
- Codiak BioSciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma
- Interventions
- LJM716
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Houston, Texas + 1 more
- Conditions
- Non-melanomatous Skin Cancer, Precancerous Condition
- Interventions
- microarray analysis, biopsy, evaluation of cancer risk factors
- Genetic · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 45 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Actinic Keratosis, Imipramine, Photodynamic Therapy
- Interventions
- Imipramine, Control Vehicle
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Dayton, Ohio
- Conditions
- Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma, Rare Lesion, Locally Advanced Malignant Neoplasm, Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Malignant Neoplasm, Metastatic Skin Squamous Cell Carcinoma, Metastatic Small Intestinal Adenocarcinoma, Rare Neoplastic Syndrome, Refractory Malignant Neoplasm, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Unresectable Malignant Neoplasm
- Interventions
- Atezolizumab, Cobimetinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Non-melanomatous Skin Cancer, Penile Cancer
- Interventions
- recombinant interferon alfa, isotretinoin
- Biological · Drug
- Lead sponsor
- Hoag Memorial Hospital Presbyterian
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 1999
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 3 more
- Conditions
- Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastroesophageal Adenocarcinoma
- Interventions
- MLN8237 (Alisertib)
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Houston, Texas • Salt Lake City, Utah
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Hepatocellular Carcinoma, Castration-resistant Prostate Cancer, Ovarian Cancer
- Interventions
- Nanrilkefusp Alfa, Pembrolizumab
- Drug
- Lead sponsor
- SOTIO Biotech AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Whittier, California • Pittsburgh, Pennsylvania
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
- Interventions
- AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Lake City, Florida + 8 more
- Conditions
- Squamous Cell Carcinoma
- Interventions
- BVEC
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
- Interventions
- Panitumumab, Talimogene Laherparepvec
- Biological
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 5
- States / cities
- New Brunswick, New Jersey • New York, New York • Durham, North Carolina